Lytix Biopharma AS

Lytix Biopharma AS has a strong liquidity position, with a current ratio of 3.91, indicating that the company holds nearly four times more current assets than current liabilities. The company's cash and equivalents amount to 12,661,000 NOK, which is a significant portion of its total assets of 45,319,000 NOK. The company's debt-to-equity ratio is 0.01, suggesting minimal leverage and a conservative capital structure. However, the company's operating cash flow is negative at -24,316,000 NOK, and its free cash flow is also negative at -17,941,000 NOK, indicating that the company is not generating positive cash from operations. In terms of profitability, Lytix Biopharma AS is currently unprofitable, with a net income of -18,183,000 NOK and an operating income of -18,685,000 NOK. The company's return on equity is -53.84%, and its return on assets is -40.12%, both of which are significantly below the industry median for biotechnology firms. These metrics suggest that the company is not effectively utilizing its equity or assets to generate returns, which is a concern for investors. The company's revenue is concentrated in a single business segment, as it does not disclose multiple operating segments in its financial statements. The geographic exposure is not explicitly detailed, but the company is headquartered in Norway, and it is likely that a significant portion of its operations and revenue are generated within the European market. The lack of geographic diversification could expose the company to regional economic or regulatory risks. Looking ahead, the company's revenue outlook is uncertain, as its most recent actual revenue was 10,526,000 NOK, while the mean analyst estimate for the next period is 33,500,000 NOK. This suggests that analysts expect a significant increase in revenue, but the company will need to demonstrate strong execution to meet these expectations. The company's capital expenditure is currently zero, indicating that it is not investing in new physical assets, which may be a strategic decision to preserve cash for research and development. The company's risk profile is relatively low in terms of liquidity and dilution, with no immediate filing-based flags detected. However, the company's negative net income and operating income indicate a high operational risk. The company's dilution potential is also low, as the number of shares outstanding for both basic and diluted shares is the same, suggesting no imminent share issuance. The company's conservative capital structure and strong cash position provide a buffer against short-term financial distress, but its long-term viability will depend on its ability to achieve profitability. Recent events, including analyst estimates and financial filings, suggest that the company is in a development phase, with a focus on research and development rather than immediate profitability. The company's mean price target of 13.00 NOK is consistent across all analyst estimates, indicating a relatively uniform view of the company's future value. The company's recent actual EPS of -0.62 NOK is in line with the mean EPS estimate of -0.60 NOK, suggesting that the company's performance is in line with analyst expectations.